Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 10;9:8362. doi: 10.1038/s41598-019-42847-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

GM1 treatment reduces the size of α-synuclein-positive aggregates in the striatum. (A) The size distributions of striatal α-synuclein-positive aggregates in saline-treated (N = 6) (red bars) compared to early start GM1-treated (blue bars) animals (N = 6) were significantly different (Kolmogorov-Smirnov D = 0.2945, P < 0.0001), with a clear shift to larger numbers of smaller sized aggregates and fewer larger sized aggregates in the early GM1 group compared to the saline-treated group. (B) The size distributions of striatal α-synuclein-positive aggregates in the delayed GM1-treated group (N = 8) (blue bars) was also significantly different (Kolmogorov-Smirnov D = 0.154, P < 0.0001) than size distribution of aggregates in the saline-treated group (N = 7) (red bars), with greater numbers of larger sized aggregates in the saline-treated group compared to the GM1 group. (C) Photomicrographs of α-synuclein immunohistochemical staining in the striatum of saline-treated (left) and early start GM1-treated (right) animals. Sizes of aggregates are notably smaller in the GM1-treated animal. Arrow points to large α-synuclein-positive aggregate. (D) Photomicrographs of α-synuclein immunohistochemical staining in the striatum of saline-treated (left) and delayed start GM1-treated (right) animals. Sizes of aggregates are smaller in the delayed start GM1-treated animal, but the effect was not as dramatic as in the early-start GM1 animals. Arrow points to large α-synuclein-positive aggregate.